Abuse deterrent formulations of opioid medications (ADOs) may help curtail the widespread abuse, misuse, and diversion of these products.With the exception of oxycodone, little information exists regarding the impact of abuse deterrent products on reducing abuse/misuse of opioid products.Studies have shown that Medicaid patients are dispensed opioids at a higher rate, abuse opioids at a higher rate, and experience more morbidity and mortality than other populations. In this study we seek to quantify misuse, abuse, dependence, and health resource use in a Medicaid patient sample prescribed an abuse deterrent formulation of extended release morphine (EMBEDA®) or non-abuse deterrent extended release morphine (ERM).
Clinical Trials in Children with Impaired Mental Capacity
Download this resource to learn how to conduct studies with patients who lack legal competence and the 4 ethical pillars of medical research.
Mindfulness with Roger Pelletier
Stop—take a breath. Notice it. Notice your body relax. Become aware of where you are. Acknowledge your thoughts, but don’t cling to them. Let them go.
Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes
Conducting clinical trials in rare diseases and advancing research pipelines requires a collaborative, multi-stakeholder approach. This process…